# US 2001/0055565 A1 · Method of detecting cyclooxygenase-2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0055565 A1
- Document ID: US20010055565A1
- Status: Published application
- Kind: A1
- Application number: 09/756,893
- Filed: 2001-01-09
- Published: 2001-12-27
- Earliest claimed: 1995-10-17
- Assignees: G.D. Searle & Co.
- Inventors: Peter C. Isakson; Karen Seibert; John J. Talley
- Web page: https://patentgrep.com/patent/US20010055565A1

## CPC

- A61K 49/06: Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K 51/04: Organic compounds
- A61K 51/0453: {having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole}
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61K 2123/00: Preparations for testing in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a method of detecting concentrations of cyclooxygenase-2 in a mammal, the method comprising: administering to the mammal a diagnostically effective amount of a cyclooxygenase-2 selective agent, which is capable of being detected in vivo; and b) detecting the agent so the concentration of cyclooxygenase-2 is detected.

## Claims

### Claim 1

A method of detecting a concentration of cyclooxygenase-2 in a mammal, the method comprising:
a) administering to the mammal a diagnostically effective amount of a cyclooxygenase-2 selective agent, which is capable of being detected in vivo; and
b) detecting the agent so the concentration of cyclooxygenase-2 is detected.

### Claim 2 (depends on 1)

The method of claim 1 wherein the agent is prepared by labeling a cyclooxygenase-2 selective compound with an isotope capable of being detected in vivo.

### Claim 3 (depends on 2)

The method of claim 2 wherein the compound is selected from compounds of Formula I
24
wherein A is a ring substituent selected from partially unsaturated heterocyclyl, heteroaryl, cycloalkenyl and aryl;
wherein R1 is at least one substituent selected from heteroaryl, cycloalkyl, cycloalkenyl and aryl, wherein R1 is substituted with one or more radicals convertible to a detectable isotope;
wherein R2 is methyl or amino; and
wherein R3 is one or more radicals selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclooxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclo, cycloalkenyl, aralkyl, heterocycloalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; or a pharmaceutically-acceptable salt or prodrug thereof.

### Claim 4 (depends on 3)

The method of claim 3 wherein A is a radical selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, benzofuryl, indenyl, benzothienyl, isoxazolyl, pyrazolyl, cyclopentenyl, cyclopentadienyl, benzindazolyl, benzopyranopyrazolyl, phenyl, and pyridyl; wherein R1 is selected from 5- and 6-membered heteroaryl, and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is substituted at a substitutable position with one or more radicals selected from hydroxy, alkoxy, nitro, triflate, halo, and formyl; wherein R2 is methyl or amino; and wherein R3 is a radical selected from hydrido, oxo, cyano, carboxyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, halo, lower alkyl, lower alkyloxy, lower cycloalkyl, phenyl, lower haloalkyl, 5- or 6-membered heterocyclo, lower hydroxylalkyl, lower aralkyl, acyl, phenylcarbonyl, lower alkoxyalkyl, 5- or 6-membered heteroaryloxy, aminocarbonyl, lower alkylaminocarbonyl, lower alkylamino, lower aminoalkyl, lower alkylaminoalkyl, phenyloxy, and lower aralkoxy; or a pharmaceutically-acceptable salt or prodrug thereof.

### Claim 5 (depends on 4)

The method of claim 4 wherein A is selected from furyl, oxazolyl, isoxazolyl, imidazolyl, and pyrazolyl; wherein R1 is phenyl substituted at a substitutable position with one or more radicals selected from hydroxy, nitro, triflate, halo, and formyl; wherein R2 is methyl or amino; and wherein R3 is a radical selected from hydrido, oxo, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, carboxypropyl, carboxymethyl, carboxyethyl, cyanomethyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, cyclohexyl, phenyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, pyrazinyl, hydroxylmethyl, hydroxylpropyl, benzyl, formyl, phenylcarbonyl, methoxymethyl, furylmethyloxy, aminocarbonyl, N-methylaminocarbonyl, N,N-dimethylaminocarbonyl, N,N-dimethylamino, N-ethylamino, N,N-dipropylamino, N-butylamino, N-methyl-N-ethylamino, aminomethyl, N,N-dimethylaminomethyl, N-methyl-N-ethylaminomethyl, benzyloxy, and phenyloxy; or a pharmaceutically-acceptable salt or prodrug thereof.

### Claim 6 (depends on 5)

The method of claim 5 wherein the agent is selected from compounds, and pharmaceutically acceptable salts and prodrug thereof, of the group consisting of
4-[3-(hydroxymethyl)-5-(4-nitrophenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(4-hydroxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-hydroxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(hydroxymethyl)-5-(4-hydroxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-hydroxy-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;
4-[2-(4-hydroxypyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
4-[5-methyl-3-(4-hydroxyphenyl)isoxazol-4-yl]benzenesulfonamide;
4-[5-hydroxymethyl-3-(4-hydroxyphenyl)isoxazol-4-yl]benzenesulfonamide;
4-[2-methyl-4-(4-hydroxyphenyl)-5-oxazolyl]benzenesulfonamide;
4-[5-(4-hydroxyphenyl)-2-(trifluoromethyl)-4-oxazolyl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(3-iodo-4-hydroxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(3-iodo-4-hydroxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(hydroxymethyl)-5-(3-iodo-4-hydroxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(4-nitrophenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(4-nitrophenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-nitro-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;
4-[2-(4-nitropyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
4-[5-methyl-3-(4-nitrophenyl)isoxazol-4-yl]benzenesulfonamide;
4-[5-hydroxymethyl-3-(4-nitrophenyl)isoxazol-4-yl]benzenesulfonamide;
4-[2-methyl-4-(4-nitrophenyl)-5-oxazolyl]benzenesulfonamide; and
4-[5-(4-nitrophenyl)-2-(trifluoromethyl)-4-oxazolyl]benzenesulfonamide.

### Claim 7 (depends on 2)

The method of claim 2, wherein the isotope is capable of being detected by PET.

### Claim 8 (depends on 7)

The method of claim 7, wherein the compound is labeled with one or more isotopes selected from 11C, 123I, 73Se, 76Br, 77Br, and 18F.

### Claim 9 (depends on 7)

The method of claim 7, wherein the compound is labeled with 11C or 18F.

### Claim 10 (depends on 1)

The method of claim 1 wherein the detected cyclooxygenase-2 is associated with a condition selected from inflammation, arthritis, neoplasia and central nervous system disorders.

### Claim 11 (depends on 1)

The method of claim 1 wherein the agent is selected from compounds, and pharmaceutically acceptable salts thereof, of the group consisting of
4-[3-(hydroxymethyl)-5-[4-(18F)fluorophenyl]-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-[4-(11C)methoxyphenyl]-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-[4-(11C)methoxyphenyl]-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(hydroxymethyl)-5-[4-(11C)methoxyphenyl]-1H-pyrazol-1-yl]benzenesulfonamide;
4-(11C)methoxy-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;
4-[2-[4-(11C)methoxypyridin-3-yl]-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
4-[5-methyl-3-[4-(11C)methoxyphenyl]isoxazol-4-yl]benzenesulfonamide;
4-[5-hydroxymethyl-3-[4-(11C)methoxyphenyl]isoxazol-4-yl]benzenesulfonamide;
4-[2-methyl-4-[4-(11C)methoxyphenyl]-5-oxazolyl]benzenesulfonamide;
4-[5-[4-(11C)methoxyphenyl]-2-(trifluoromethyl)-4-oxazolyl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-[3-(125I) iodo-4-(11C)methoxyphenyl]-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-[3-(125I)iodo-4-(11C)methoxyphenyl]-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(hydroxymethyl)-5-[3-(125I)iodo-4-(11C)methoxyphenyl]-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-[4-(18F)fluorophenyl]-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-[4-(18F)fluorophenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-[4-(18F)fluorophenyl]-1H-pyrazol-1-yl]benzenesulfonamide;
4-(18F)fluoro-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;
4-[2-(4-(18F)fluoropyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
4-[5-methyl-3-[4-(18F)fluorophenyl]isoxazol-4-yl]benzenesulfonamide;
4-[5-hydroxymethyl-3-[4-(18F)fluorophenyl]isoxazol-4-yl]benzenesulfonamide;
4-[2-methyl-4-[4-(18F)fluorophenyl]-5-oxazolyl]benzenesulfonamide; and
4-[5-[4-(18F)fluorophenyl]-2-(trifluoromethyl)-4-oxazolyl]benzenesulfonamide.

### Claim 12

A method of localizing and quantifying cyclooxygenase-2 in a mammal, said method comprising
a) preparing a labeled compound, which selectively binds to cyclooxygenase-2 and which contains an isotope capable of emitting radiation;
b) administering to said mammal a diagnostically effective amount of the labeled compound; and
c) detecting an emission from the compound administered to the mammal so that the cyclooxygenase-2 in the mammal is localized.

### Claim 13 (depends on 12)

The method of claim 12 wherein the emission is detected by an technique selected from MRI, SPECT and PET.

### Claim 14 (depends on 13)

The method of claim 13 wherein the emission is detected by PET.

### Claim 15 (depends on 12)

The method of claim 12 wherein the isotope is capable of emitting gamma or positron radiation.

### Claim 16 (depends on 15)

The method of claim 15 wherein the isotope is selected from isotopes of carbon, oxygen, nitrogen, selenium, bromine, iodine and fluorine.

### Claim 17 (depends on 16)

The method of claim 16, wherein the compound is labeled with one or more isotopes selected from 11C, 123I, 73Se, 76Br, 77Br, and 18F.

### Claim 18 (depends on 17)

The method of claim 17 wherein the isotope is 18F or 11C.

### Claim 19

A method of preparing a labeled cyclooxygenase-2 inhibitor, said method comprising halide exchange of a nitro radical or alkylation of alcohols

### Claim 20

A method of detecting neoplasia in a mammal, said method comprising a) preparing a compound which selectively binds to cyclooxygenase-2 and which is labeled with an isotope capable of emitting gamma or positron radiation b) administering to said mammal a diagnostically effective amount of the labeled compound; and c) detecting an emission from the compound administered to the mammal so that the neoplasia in the mammal is localized.

### Claim 21 (depends on 20)

The method of claim 20, wherein the compound is labeled with one or more isotopes selected from 11C, 123I, 73Se, 76Br, 77Br, and 18F.

### Claim 22

A method of localizing and quantifying cyclooxygenase-2 in a mammal, the method comprising:
a) preparing a compound which selectively binds to cyclooxygenase-2 and which is labeled with an isotope capable of emitting gamma radiation;
b) administering to said mammal a diagnostically effective amount of the labeled compound; and
c) detecting the gamma emission from the compound administered to the mammal so that the cyclooxygenase-2 in the mammal is localized.

### Claim 23 (depends on 22)

The method of claim 22, wherein the compound is labeled with one or more isotopes selected from 125I.

### Claim 24 (depends on 23)

The method of claim 23 wherein the cyclooxygenase-2 concentration is associated with a condition selected from inflammation, arthritis, neoplasia and central nervous system disorders.

### Claim 25

A pharmaceutical composition for detecting a concentration of cyclooxygenase-2 comprising a pharmaceutically-acceptable carrier and optimally, at least one pharmaceutically-acceptable adjuvant; and an active substance comprising a diagnostically-effective amount of a compound which is capable of being detected in vivo.

### Claim 26

A pharmaceutical composition for detecting a concentration of cyclooxygenase-2 comprising a pharmaceutically-acceptable carrier and optimally, at least one pharmaceutically-acceptable adjuvant; and an active substance comprising a diagnostically-effective amount of a compound which is labeled with an isotope capable of emitting gamma or positron radiation.
